dm+d

Unassigned

New Medicines

Stage IIb-III malignant melanoma - post-resection

Information

New molecular entity
Polynoma
Polynoma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Polyvalent melanoma vaccine using a combination of shed antigens produced by three proprietary melanoma cell lines
UK incidence of malignant melanoma is about 21 per 100,000 people, and is doubling every 10-20 years. 7% of 15-64 year olds present with advanced (III/IV) disease compared with 20% aged ≥65.
Stage IIb-III malignant melanoma - post-resection
Intradermal

Evidence based evaluations